Idorsia launches Phase 2 psoriasis trial in 30 patients of oral CCR6 antagonist, readout due Q1 2027

IDRSFIDRSF•134d ago

On January 6, 2026 Idorsia initiated a placebo-controlled Phase 2 trial of oral CCR6 antagonist IDOR-1117-2520 in 30 moderate-to-severe psoriasis patients, measuring PASI score; data are expected in Q1 2027. IDOR-1117-2520, a CCR6 antagonist, blocks Th17 cell migration via CCR6/CCL20 axis and could enable expansion into other Th17-driven autoimmune indications.

Sources

GGG

Idorsia launches Phase 2 psoriasis trial in 30 patients of oral CCR6 antagonist, readout due Q1 2027

Related News

TJX Beats Q1 EPS by $0.20, Comps Up 6% and Spain Store Launch

Meta Secures Tens of Thousands MWh Storage Deals, Cuts 10% Workforce

Urban Outfitters Q1 Sales Soar 11% to $1.5B, EPS Up 12%

Exodus Movement April XO Swap Volume Up 44% to $98M, Global Pay Launch

Atossa’s Manuscript on (Z)-Endoxifen Utrophin Modulation Accepted for Publication

Sources

Ask about IDRSF

Idorsia launches Phase 2 psoriasis trial in 30 patients of oral CCR6 antagonist, readout due Q1 2027

Related News

TJX Beats Q1 EPS by $0.20, Comps Up 6% and Spain Store Launch

Meta Secures Tens of Thousands MWh Storage Deals, Cuts 10% Workforce

Urban Outfitters Q1 Sales Soar 11% to $1.5B, EPS Up 12%

Exodus Movement April XO Swap Volume Up 44% to $98M, Global Pay Launch

Atossa’s Manuscript on (Z)-Endoxifen Utrophin Modulation Accepted for Publication

Sources